Dashboard
Manage Tickers

QNCX Quince Therapeutics, Inc.

Nasdaq quincetx.com


$ 1.78 $ -0.02 (-1.12 %)    

Friday, 24-Oct-2025 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.76
$ 1.75
$ 1.70 x 1,000
$ 1.94 x 15
$ 1.75 - $ 1.85
$ 0.72 - $ 2.45
125,204
na
94.54M
$ 0.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 10-29-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 06-12-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

quince-therapeutics-announces-poster-presentation-of-patient-reported-walking-capacity-in-children-with-ataxia-telangiectasia-at-54th-cns-annual-meeting
Quince Therapeutics Announces Poster Prese...
10/09/2025 20:08:00

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's...

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-4-price-target
D. Boral Capital Maintains Buy on Quince T...
09/26/2025 11:27:40

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ: QNCX) with a Buy and maintains $4 price target.

quince-therapeutics-publishes-advanced-pk-modeling-study-of-phase-3-asset-edsp-in-a-t-patients-and-healthy-adults-in-ascpt-journal-psp
Quince Therapeutics Publishes Advanced PK ...
09/25/2025 20:07:25

Quince Therapeutics, Inc.

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-4-price-target
D. Boral Capital Maintains Buy on Quince T...
08/15/2025 11:19:25

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $4 price target.

jmp-securities-maintains-market-outperform-on-quince-therapeutics-lowers-price-target-to-8
JMP Securities Maintains Market Outperform...
08/12/2025 13:12:23

JMP Securities analyst Jonathan Wolleben maintains Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform and lowers the...

quince-therapeutics-q2-eps-034-misses-026-estimate
Quince Therapeutics Q2 EPS $(0.34) Misses ...
08/11/2025 20:19:33

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of...

Core News & Articles
Quince Therapeutics Enters Strategic Relat...
08/07/2025 12:09:32

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's...

this-lionsgate-studios-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday
This Lionsgate Studios Analyst Begins Cove...
08/05/2025 13:04:48

jmp-securities-initiates-coverage-on-quince-therapeutics-with-market-outperform-rating-announces-price-target-of-9
JMP Securities Initiates Coverage On Quinc...
08/05/2025 12:40:33

JMP Securities analyst Jonathan Wolleben initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform ra...

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-4-price-target
D. Boral Capital Maintains Buy on Quince T...
07/17/2025 12:37:50

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $4 price target.

quince-therapeutics-completes-enrollment-in-pivotal-phase-3-neat-clinical-trial-to-evaluate-edsp-for-treatment-of-rare-neurodegenerative-disease-ataxia-telangiectasia
Quince Therapeutics Completes Enrollment I...
07/16/2025 12:06:35

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-4-price-target
D. Boral Capital Maintains Buy on Quince T...
06/13/2025 11:54:45

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $4 price target.

quince-therapeutics-reveals-pricing-of-up-to-22m-private-placement-of-securities-financing-to-provide-115m-upfront-104m-from-warrants-proceeds-to-fund-phase-3-neat-trial-and-corporate-purposes
Quince Therapeutics Reveals Pricing Of Up ...
06/12/2025 21:19:45

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-4-price-target
D. Boral Capital Maintains Buy on Quince T...
06/04/2025 11:48:24

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $4 price target.

quince-therapeutics-says-pivotal-phase-3-neat-clinical-trial-in-rare-neurodegenerative-disease-a-t-reaches-important-milestone-as-enrollment-now-exceeds-75
Quince Therapeutics Says Pivotal Phase 3 N...
06/03/2025 20:12:51

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's...

why-faraday-future-intelligent-electric-shares-are-trading-higher-by-6-here-are-20-stocks-moving-premarket
Why Faraday Future Intelligent Electric Sh...
05/05/2025 09:51:32

d-boral-capital-maintains-buy-on-quince-therapeutics-lowers-price-target-to-4
D. Boral Capital Maintains Buy on Quince T...
03/25/2025 11:20:04

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and lowers the price target fr...

oppenheimer-initiates-coverage-on-quince-therapeutics-with-outperform-rating-announces-price-target-of-10
Oppenheimer Initiates Coverage On Quince T...
03/24/2025 11:48:39

Oppenheimer analyst Leland Gershell initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and ann...

d-boral-capital-maintains-buy-on-quince-therapeutics-maintains-12-price-target
D. Boral Capital Maintains Buy on Quince T...
02/05/2025 12:05:52

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $12 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION